Large-Scale Production of Cardiomyocytes from Human Pluripotent Stem Cells Using a Highly Reproducible Small Molecule-Based Differentiation Protocol

Hananeh Fonoudi; Hassan Ansari; Saeed Abbasalizadeh; Gillian M Blue; Nasser Aghdami; David S Winlaw; Richard P Harvey; Alexis Bosman; Hossein Baharvand

doi:10.3791/54276

Journal

/

발생학

/

고도의 재현 작은 분자 기반의 차별화 프로토콜을 사용하여 인간 다 능성 줄기 세포로부터 심근 세포의 대규모 생산

Large-Scale Production of Cardiomyocytes from Human Pluripotent Stem Cells Using a Highly Reproducible Small Molecule-Based Differentiation Protocol

JoVE 신문
발생학

JoVE 비디오를 활용하시려면 도서관을 통한 기관 구독이 필요합니다. 전체 비디오를 보시려면 로그인하거나 무료 트라이얼을 시작하세요.

JoVE 신문 발생학

Large-Scale Production of Cardiomyocytes from Human Pluripotent Stem Cells Using a Highly Reproducible Small Molecule-Based Differentiation Protocol

고도의 재현 작은 분자 기반의 차별화 프로토콜을 사용하여 인간 다 능성 줄기 세포로부터 심근 세포의 대규모 생산

Please note that all translations are automatically generated. Click here for the English version.

10,508 Views

•

12:21 min

•

July 25, 2016

DOI:

10.3791/54276-v

DOI:

10.3791/54276-v

•

12:21 min

July 25, 2016

•

2 Views

Hananeh Fonoudi*^1,2,3,8, Hassan Ansari*^1,8, Saeed Abbasalizadeh¹, Gillian M Blue^6,7, Nasser Aghdami¹, David S Winlaw^6,7, Richard P Harvey^2,3,4, Alexis Bosman*^2,3, Hossein Baharvand*^1,5

¹Department of Stem Cells and Developmental Biology, Cell Science Research Center,Royan Institute for Stem Cell Biology and Technology, ACECR, ²Developmental and Stem Cell Biology Division,Victor Chang Cardiac Research Institute, ³St. Vincent´s Clinical School, Faculty of Medicine,University of New South Wales, ⁴School of Biotechnology and Biomolecular Sciences,University of New South Wales, ⁵Department of Developmental Biology,University of Science and Culture, ⁶Heart Centre for Children,The Children´s Hospital at Westmead, ⁷Sydney Medical School,University of Sydney, ⁸Department of Developmental Biology,University of Science and Culture, Tehran, Iran

내레이션 대본

Summary

Here, we present a robust, fast and scalable cardiomyocyte differentiation protocol for human pluripotent stem cells (hPSCs). Cardiomyocytes derived using this large-scale method can provide sufficient cell numbers for their effective use in human cardiovascular disease modeling, high-throughput drug screening, and potentially clinical applications.